BioSante pancreatic cancer vaccine extends survival in early stage trial

BioSante Pharmaceuticals, Inc. announced on 27 February 2012 that results from a Phase Ib clinical study that show its GVAX Pancreas cancer vaccine increased the median survival of pancreatic cancer patients with previously treated, locally advanced or metastatic pancreatic adenocarcinoma (PDA), … Continue reading

New melanoma drug may not be funded by NHS – in spite of improved survival in some patients

The National Institute for Health and Clinical Excellence (NICE) in the UK issued new draft guidance recommending against the use of ipilumab (Yervoy, Bristol-Myers Squibb) for advanced malignant melanoma in patients who have previously received chemotherapy. The rationale for the preliminary … Continue reading

Astellas discontinue darexaban development citing intensified competition

The oral anticoagulant market is one of the few primary care markets expected to grow significantly in the next few years, with a number of the new oral thrombin inhibitors and factor Xa inhibitors set to generate peak sales well in excess of $1billion.  … Continue reading